Catalog No.
Product Name
Application
Product Information
Citations
-
Thrombin inhibitor
BIBR 953 (Dabigatran, Pradaxa) is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. It has shown antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action and predictable pharmacodynamic response.
- Tanaka M, .et al. , J Pharmacol Sci, 2016, Jul;131(3):162-71 PMID: 27426918
-
Thrombin inhibitor
BIBR-1048 (Dabigatran etexilate) is an anticoagulant from the class of the direct thrombin inhibitors. -
Thrombin inhibitor
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. -
thrombin/factor Xa dual inhibitor
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity. -
Thrombin inhibitor
Ximelagatran is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. -
Reversible thrombin inhibitor
Bivalirudin is a synthetic 20 residue peptide which reversibly inhibits thrombin. -
direct thrombin inhibitor
Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM. -
thrombin inhibitor
Dabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. -
Thrombin inhibitor
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. -
NQO2 inhibitor
Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and a thrombin inhibitor. -
thrombin inhibitor
Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity. -
Thrombin Inhibitor
Hirudin is a potent thrombin inhibitor known for its anticoagulant properties. It exhibits significant anti-thrombotic activity and is implicated in therapeutic applications such as wound repair, anti-fibrosis, and anti-tumor responses. Additionally, Hirudin has been explored for its effects on diabetic complications and cerebral hemorrhage, making it a valuable reagent in various research contexts. -
Thrombin Inhibitor
Isorhamnetin 3-O-galactoside is a flavonoid glycoside that acts as a thrombin inhibitor, isolated from Oenanthe javanica. It exhibits significant antithrombotic and profibrinolytic properties by inhibiting thrombin and factor Xa activity, thereby reducing the maximum rate of thrombin-catalyzed fibrin polymerization. Additionally, Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion and decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, making it instrumental in research on liver injury and thrombotic vascular diseases. -
NS2B-NS3/thrombin Inhibitor
5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione is a potent inhibitor of the dengue virus NS2B-NS3 protease and thrombin. This compound is valuable for studying the mechanisms of viral replication and coagulation processes, making it an essential tool in research focused on infectious diseases and related therapeutic interventions. Its dual activity highlights its potential for investigating the dynamics of viral pathology and thrombotic complications. -
Thrombin Peptide
TP508 is a 23-amino acid nonproteolytic thrombin peptide that selectively targets the receptor-binding domain of thrombin. It activates endothelial nitric oxide synthase (eNOS) and promotes nitric oxide production in human endothelial cells, facilitating enhanced endothelial cell activation and stem cell recruitment. This molecule is of significant interest for applications in tissue revascularization and regenerative medicine research. -
Thrombin Receptor Activating Peptide
TRAP-7 is a thrombin receptor (PAR) activating peptide that functions by stimulating total inositol phosphate (IP) accumulation, as well as the phosphorylation of a specific endogenous substrate for activated protein kinase C (PKC). This compound is valuable in the study of signaling pathways related to thrombosis and cardiovascular diseases, providing insights into PAR-mediated cellular responses and potential therapeutic interventions. -
Thrombin/ Factor Xa Inhibitor
Ciraparantag is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants. This compound effectively neutralizes the effects of low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. Its unique mechanism makes Ciraparantag a valuable tool for research focused on anticoagulation reversal and hemostasis. -
Thrombin/Factor Xa Inhibitor
Ciraparantag acetate is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants, including low molecular weight heparins, unfractionated heparins, and certain direct oral anticoagulants, excluding vitamin K antagonists (VKAs). Its primary mechanism targets the coagulation pathway, facilitating the restoration of normal hemostasis in clinical situations where anticoagulation reversal is necessary. Ciraparantag acetate is valuable in research applications focused on anticoagulation management and hemostatic balance in cardiovascular studies. -
Thrombin Inhibitor
Edoxaban impurity 4 is a structural impurity related to Edoxaban, a selective and potent thrombin inhibitor. It demonstrates significant biological activity and is primarily utilized in research applications focusing on anticoagulation strategies. Edoxaban itself serves as an effective anticoagulant, with its mechanistic role in inhibiting factor Xa contributing to therapeutic approaches for stroke prevention and other thromboembolic disorders. -
Thrombin/Factor Xa Inhibitor
Ciraparantag TFA is a potent thrombin and factor Xa inhibitor utilized as a broad-spectrum reversal agent for anticoagulants. It effectively antagonizes the effects of various anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and specific direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. This compound is significant for research applications focused on enhancing hemostatic management in patients receiving anticoagulant therapy. -
Thrombin/Factor Xa/Trypsin/Papain Inhibitor
Bacithrocin D is a potent inhibitor of key proteases, specifically targeting thrombin, factor Xa, trypsin, and papain. It effectively prolongs clotting time, making it valuable in studies related to coagulation and hemostasis. Bacithrocin D demonstrates IC50 values of 124 μM for thrombin, 9 μM for factor Xa, 0.85 μM for trypsin, and a remarkable 0.01 μM for papain, showcasing its high potency against these proteases. This reagent is useful for investigating protease-related pathways and developing therapeutic strategies in anticoagulation research. -
Thrombin Inhibitor
Bacithrocin A is a potent thrombin inhibitor that also targets factor Xa, trypsin, and papain, demonstrating IC50 values of 48 μM, 13 μM, 0.65 μM, and 0.02 μM, respectively. This compound is of particular interest in the study of coagulation processes and the development of anticoagulant therapies. Its broad-spectrum inhibitory activity makes it a valuable reagent for biological research focused on protease activity modulation and hemostasis. -
Thrombin Inhibitor
Bacithrocin C is a potent thrombin inhibitor that effectively targets thrombin, factor Xa, trypsin, and papain, exhibiting IC50 values of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively. This compound demonstrates significant inhibitory activity, making it a valuable tool for research in coagulation pathways and protease-related studies. It is suitable for applications focused on understanding thrombotic processes and developing antithrombotic strategies. -
Thrombin Inhibitor
Bacithrocin B is a potent thrombin inhibitor that also targets factor Xa, trypsin, and papain. It exhibits inhibitory activity with IC50 values of 84 μM for thrombin, 17 μM for factor Xa, 1.7 μM for trypsin, and 0.02 μM for papain. This compound is valuable for research applications aiming to study coagulation processes and enzyme dynamics in various biological systems. -
Thrombin Inactivator
Dermatan sulphate sodium is a glycosaminoglycan that functions as a thrombin inactivator, exhibiting significant antithrombotic activity. It selectively enhances the heparin cofactor II-mediated inactivation of thrombin without affecting antithrombin III. This compound has been shown to promote stem cell differentiation and may alleviate pulmonary fibrosis induced by Bleomycin. Dermatan sulphate sodium is utilized in research focused on cardiovascular diseases, inflammation, and stem cell biology. -
Thrombin Receptor Agonist
TRAP-14 (SFLLRNPNDKYEPF) is a synthetic peptide that acts as an agonist for the thrombin receptor. This compound is utilized in research to study thrombin signaling pathways and their implications in various physiological and pathological processes. Its ability to activate the thrombin receptor makes it valuable for investigating thrombosis, inflammation, and cardiovascular diseases. -
Thrombin Inhibitor
BAY 1217224 is a selective thrombin inhibitor that acts through competitive binding to the active site of thrombin, resulting in the inhibition of fibrinogen conversion and clot formation. This compound demonstrates favorable oral pharmacokinetics, making it suitable for in vivo studies. BAY 1217224 is primarily utilized in research focused on coagulation pathways and the development of anticoagulant therapies. -
Thrombin Inhibitor
(2S,4S)-Argatroban is a potent inhibitor of human thrombin, exhibiting a Ki value of 280 μM. This compound is primarily utilized in research focused on thrombotic diseases and coagulation disorders. Its mechanism of action provides a valuable tool for studying thrombin's role in physiology and pathology, as well as for the development of therapeutic strategies targeting blood coagulation pathways. -
Thrombin Inhibitor
Corthrombin is a highly potent alpha-keto-amide thrombin inhibitor, exhibiting a Ki value of 1 pM. This compound is utilized in the study of cardiovascular diseases, providing valuable insights into thrombin-related mechanisms and potential therapeutic interventions. Its high specificity and efficacy make it an essential tool for research focused on coagulation processes and thrombotic disorders. -
Thrombin Receptor Antagonist
Thrombin receptor peptide ligand is a selective antagonist of the thrombin receptor, inhibiting its activation and downstream signaling. This compound exhibits antithrombotic properties, making it suitable for research focused on thrombotic disorders and cardiovascular diseases. Its ability to modulate thrombin activity positions it as a valuable tool for studying platelet aggregation and related pathways. -
Thrombin Inhibitor
Flovagatran is a potent and reversible thrombin inhibitor, characterized by a Ki value of 9 nM. This compound is primarily utilized in research related to arterial and venous thrombosis, providing valuable insights into thrombotic mechanisms and potential therapeutic interventions. -
Thrombin Inhibitor
Hirullin P18 is a potent thrombin inhibitor that effectively modulates coagulation pathways. This compound exhibits significant anticoagulant activity, making it valuable for research applications focused on thrombus formation and cardiovascular disorders. Hirullin P18 is an essential tool for studying thrombin-related biological processes and developing therapeutic strategies for thrombotic diseases. -
Thrombin Inhibitor
Sofigatran is an orally active thrombin inhibitor that functions as an anticoagulant by selectively targeting factor IIa. This compound exhibits significant biological activity in modulating blood coagulation pathways and is particularly relevant in cardiovascular disease research. Its utility in preclinical studies facilitates the exploration of its therapeutic potential in managing thrombotic disorders. -
Neutral Thrombin Inhibitor
AZD-8165 is a highly selective neutral thrombin inhibitor that demonstrates potent anticoagulant properties. This compound is primarily utilized in research related to cardiovascular diseases, including hypertension and heart failure. Its mechanism of action aids in elucidating thrombotic processes and evaluating therapeutic strategies in related cardiovascular conditions. -
α-Thrombin Substrate
Sar-Pro-Arg-pNA serves as a chromogenic substrate specifically for α-thrombin. It enables the assessment of α-thrombin activity through colorimetric measurements, making it a valuable tool in coagulation studies and thrombin activity assays. This substrate is suitable for research applications that investigate thrombin's role in hemostasis and related disorders. -
Thrombin Inhibitor
L 373890 is a selective thrombin inhibitor characterized by its low Ki value of 0.5 nM, indicating potent activity against thrombin. This compound exhibits high selectivity, showing a significantly reduced Ki of 570 nM for trypsin and minimal inhibition of other serine proteases, such as plasmin and tPA. L 373890 is a valuable tool for researchers investigating thrombosis and related cardiovascular disorders. -
Thrombin Inhibitor
Efegatran is a potent thrombin inhibitor that effectively prevents platelet aggregation. Its anticoagulant and antithrombotic properties make it valuable for research applications focused on cardiovascular health and clotting disorders. This compound serves as an important tool for studying thrombin-related mechanisms and evaluating potential therapeutic strategies in the management of thromboembolic diseases. -
Thrombin Inhibitor
Atecegatran TFA is a selective direct thrombin inhibitor that acts as a potent anticoagulant. It plays a significant role in the management of cardiovascular diseases by effectively inhibiting thrombin, thereby preventing thrombus formation. The active form of this compound, AR-H067637, is critical for its anticoagulation effects and is utilized in various research applications focused on thrombotic disorders and cardiovascular health. -
Thrombin Inhibitor
CVS-1123 is an orally active direct thrombin inhibitor targeting thrombin activity. This compound effectively inhibits in vitro platelet aggregation induced by γ-thrombin and prolongs activated partial thromboplastin time. CVS-1123 modulates the thrombotic response to deep vessel wall injury in both arterial and venous systems, making it a valuable tool for antithrombotic research. -
Thrombin Cleavable Peptide
Thrombin-cleavable peptide targets thrombin and is specifically designed for thrombin recognition and cleavage. Upon enzymatic cleavage, it releases thrombolytic peptides that play a crucial role in initiating thrombolysis. This reagent is valuable for research applications related to ischemic stroke and other thrombotic conditions. -
Thrombin Inhibitor
(2R)-Atecegatran is a selective thrombin inhibitor that demonstrates significant anticoagulant activity. This compound is employed in research concerning thromboembolic disorders, aiding in the understanding of coagulation pathways and potential therapeutic strategies. Its effectiveness in modulating thrombin activity makes it a valuable tool in the development of anticoagulant therapies. -
Thrombin Inhibitor
S-18326 is an orally active direct thrombin inhibitor that functions by reversibly binding to the active site of thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombus formation. This compound effectively prolongs clotting times in human plasma and has shown antithrombotic efficacy in various animal models while maintaining normal platelet levels. S-18326 is suitable for research applications related to thromboembolic diseases. -
Thrombin/Factor Xa Inhibitor
SAR107375 is a potent dual inhibitor of thrombin and factor Xa, exhibiting Ki values of 1 nM for factor Xa and 8 nM for thrombin. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and coagulation disorders. SAR107375 can be utilized in the study of cardiovascular diseases and the development of novel anticoagulant therapies. -
Thrombin Inhibitor
Thrombin Inhibitor 6 is a highly potent anticoagulant that functions by specifically inhibiting thrombin with an IC50 of 1 nM. This compound is valuable for research applications in anticoagulant therapy and thrombotic disease studies, enabling the exploration of thrombin's role in hemostasis and thrombosis.
